CoChat

Development of protective anti-Mycoplasma pneumoniae antibodies after immunization of guinea pigs with the combination of a P1-P30 chimeric recombinant protein and chitosan.

Hausner, Marius, Schamberger, Anna, Naumann, Wolfgang, Jacobs, Enno, Dumke, Roger · 2013 · Microbial Pathogenesis
Cited by 29

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.micpath.2013.07.004

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 42

  1. Atkinson, 2008, Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections, FEMS Microbiol Rev, 32, 956, 10.1111/j.1574-6976.2008.00129.x · DOI · Paper page
  2. von Baum, 2009, Mycoplasma pneumoniae pneumonia revisited within the German competence network for community-acquired pneumonia (CAPNETZ), BMC Infect Dis, 9, 62, 10.1186/1471-2334-9-62 · DOI
  3. Tsiodras, 2005, Central nervous system manifestations of Mycoplasma pneumoniae infections, J Infect, 51, 343
  4. Zhao, 2013, Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012, Antimicrob Agents Chemother, 57, 1521, 10.1128/AAC.02060-12 · DOI
  5. Linchevski, 2009, Mycoplasma pneumonia vaccine protection efficiency and adverse reactions – systematic review and meta-analysis, Vaccine, 27, 2437, 10.1016/j.vaccine.2009.01.135 · DOI
  6. Dandekar, 2000, Re-annotating the Mycoplasma pneumoniae genome sequence: adding value, function and reading frames, Nucleic Acids Res, 28, 3278, 10.1093/nar/28.17.3278 · DOI · Paper page
  7. Hames, 2009, Glycerol metabolism is important for cytotoxicity of Mycoplasma pneumoniae, J Bacteriol, 191, 747, 10.1128/JB.01103-08 · DOI · Paper page
  8. Schmidl, 2011, A trigger enzyme in Mycoplasma pneumoniae: impact of the glycerophosphodiesterase GlpQ on virulence and gene expression, PLoS Pathog, 7, e1002263, 10.1371/journal.ppat.1002263 · DOI · Paper page
  9. Kannan, 2006, ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens, Proc Natl Acad Sci U S A, 103, 6724, 10.1073/pnas.0510644103 · DOI · Paper page
  10. Krause, 2004, Cellular engineering in a minimal microbe: structure and assembly of the terminal organelle of Mycoplasma pneumoniae, Mol Microbiol, 51, 917, 10.1046/j.1365-2958.2003.03899.x · DOI
  11. Balish, 2006, Mycoplasmas: a distinct cytoskeleton for wall-less bacteria, J Mol Microbiol Biotechnol, 11, 244, 10.1159/000094058 · DOI
  12. Schurwanz, 2009, A strategy to create chimeric proteins derived from functional adhesin regions of Mycoplasma pneumoniae for vaccine development, Infect Immun, 77, 5007, 10.1128/IAI.00268-09 · DOI · Paper page
  13. Romero-Arroyo, 1999, Mycoplasma pneumoniae protein P30 is required for cytadherence and associated with proper cell development, J Bacteriol, 181, 1079, 10.1128/JB.181.4.1079-1087.1999 · DOI
  14. Lamm, 1997, Interaction of antigens and antibodies at mucosal surfaces, Ann Rev Microbiol, 51, 311, 10.1146/annurev.micro.51.1.311 · DOI · Paper page
  15. Arca, 2009, Chitosan-based systems for the delivery of vaccine antigens, Expert Rev Vaccines, 8, 937, 10.1586/erv.09.47 · DOI · Paper page
  16. Pavot, 2012, New insights in mucosal vaccine development, Vaccine, 30, 142, 10.1016/j.vaccine.2011.11.003 · DOI · Paper page
  17. Dumke, 2008, Characterisation of subtype and variant-specific antigen regions of the P1 adhesin of Mycoplasma pneumoniae, Int J Med Microbiol, 298, 483, 10.1016/j.ijmm.2007.06.002 · DOI
  18. Dumke, 2007, Sensitive detection of Mycoplasma pneumoniae in human respiratory tract samples by optimized real-time PCR approach, J Clin Microbiol, 45, 2726, 10.1128/JCM.00321-07 · DOI
  19. Berger, 2004, Structure and interactions in chitosan hydrogels by complexation or aggregation for biomedical application, Eur J Pharm Biopharm, 57, 35, 10.1016/S0939-6411(03)00160-7 · DOI · Paper page
  20. Korsmeyer, 1982, Mechanism of solute release from porous hydrophilic polymers, Int J Pharm, 15, 25, 10.1016/0378-5173(83)90064-9 · DOI · Paper page
  21. Waring, 2001, Development of a genomics-based PCR assay for detection of Mycoplasma pneumoniae in a large outbreak in New York State, J Clin Microbiol, 39, 1385, 10.1128/JCM.39.4.1385-1390.2001 · DOI
  22. Klement, 2006, Identification of risk factors for infection in an outbreak of Mycoplasma pneumoniae respiratory tract disease, Clin Infect Dis, 43, 1239, 10.1086/508458 · DOI
  23. Walter, 2008, Community outbreak of Mycoplasma pneumoniae infection: school-based cluster of neurologic disease associated with household transmission of respiratory illness, J Infect Dis, 198, 1365, 10.1086/592281 · DOI
  24. Sliman, 2009, Outbreak of acute respiratory disease caused by Mycoplasma pneumoniae on board a deployed U.S. navy ship, J Clin Microbiol, 47, 4121, 10.1128/JCM.01926-09 · doi:10.1128/jcm.01926-09
  25. Pereyre, 2012, Clonal spread of Mycoplasma pneumoniae in primary school, Bordeaux, France, Emerg Infect Dis, 18, 343, 10.3201/eid1802.111379 · DOI
  26. Barile, 1988, Immunization against Mycoplasma pneumoniae disease: a review, Isr J Med Sci, 20, 912
  27. Barile, 1988, Hamster challenge potency assay for evaluation of Mycoplasma pneumoniae vaccines, Infect Immun, 56, 2450, 10.1128/IAI.56.9.2450-2457.1988 · DOI
  28. Couch, 1964, Infection with artificially propagated Eaton agent (Mycoplasma pneumoniae). Implications for development of attenuated vaccine for cold agglutinin-positive pneumonia, J Am Med Assoc, 187, 442, 10.1001/jama.1964.03060190058015 · DOI
  29. Smith, 1967, Inactivated Mycoplasma pneumoniae vaccine. Evaluation in volunteers, J Am Med Assoc, 199, 353, 10.1001/jama.1967.03120060051007 · doi:10.1001/jama.1967.03120060051007
  30. Su, 1990, Sequence divergency of the cytadhesin gene of Mycoplasma pneumoniae, Infect Immun, 58, 2669, 10.1128/IAI.58.8.2669-2674.1990 · DOI
  31. Layh-Schmitt, 1997, The adhesin related 30-kDa protein of Mycoplasma pneumoniae exhibits size and antigen variability, FEMS Microbiol Lett, 152, 101, 10.1111/j.1574-6968.1997.tb10415.x · doi:10.1111/j.1574-6968.1997.tb10415.x
  32. Brandtzaeg, 2003, Role of secretory antibodies in the defence against infections, Int J Med Microbiol, 293, 3, 10.1078/1438-4221-00241 · DOI · Paper page
  33. Oliveira, 2007, Intranasal vaccines for protection against respiratory and systemic bacterial infections, Expert Rev Vaccines, 6, 419, 10.1586/14760584.6.3.419 · doi:10.1586/14760584.6.3.419
  34. Lee, 2000, Bioadhesive-based dosage forms: the next generation, J Pharm Sci, 89, 850, 10.1002/1520-6017(200007)89:7<850::AID-JPS2>3.0.CO;2-G · DOI · Paper page
  35. Illum, 2001, Chitosan as a novel nasal delivery system for vaccines, Adv Drug Deliv Rev, 51, 81, 10.1016/S0169-409X(01)00171-5 · DOI · Paper page
  36. Ralli-Jain, 2010, Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization, Vaccine, 28, 7659, 10.1016/j.vaccine.2010.09.040 · doi:10.1016/j.vaccine.2010.09.040
  37. Crouch, 2005, The use of a systemic prime/mucosal boost strategy with an equine influenza ISCOM vaccine to induce protective immunity in horses, Vet Immunol Immunopathol, 108, 345, 10.1016/j.vetimm.2005.06.009 · doi:10.1016/j.vetimm.2005.06.009
  38. McCluskie, 2002, Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA, FEMS Immunol Med Microbiol, 32, 179, 10.1111/j.1574-695X.2002.tb00551.x · doi:10.1111/j.1574-695x.2002.tb00551.x
  39. Davenport, 2000, A homing selection hypothesis for T-cell trafficking, Immunol Today, 21, 315, 10.1016/S0167-5699(00)01644-3 · doi:10.1016/s0167-5699(00)01644-3
  40. Bellanti, 2004, Immunologic studies of specific mucosal and systemic immune responses in Mexican school children after booster aerosol or subcutaneous immunization with measles vaccine, Vaccine, 22, 1214, 10.1016/j.vaccine.2003.09.032 · doi:10.1016/j.vaccine.2003.09.032
  41. Baumann, 2008, Mucosal vaccination against bacterial respiratory infections, Expert Rev Vaccines, 7, 1257, 10.1586/14760584.7.8.1257 · DOI
  42. Baudner, 2005, Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform, J Drug Target, 13, 489, 10.1080/10611860500353195 · doi:10.1080/10611860500353195

Cited by

See all 29

Metadata

Authors
Hausner, M., Schamberger, A., Naumann, W., Jacobs, E., & Dumke, R.
Venue
Microbial Pathogenesis
Publisher
Elsevier BV
Published
2013-11
Volume
64
Pages
23-32
ISSN
0882-4010
Cited by
29
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.